Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
Li Shen(The University of Texas MD Anderson Cancer Center), Роберто Пили(Sidney Kimmel Cancer Center), Tomas Leanderson(Lund University), Anders Olsson(Linköping University), Michael J. Ciesielski(Roswell Park Comprehensive Cancer Center), Swathi Ramakrishnan(Roswell Park Comprehensive Cancer Center), Robert A. Fenstermaker(Roswell Park Comprehensive Cancer Center), Scott I. Abrams(Roswell Park Comprehensive Cancer Center), Helena Eriksson(Active Biotech (Sweden)), Kiersten Marie Miles(Roswell Park Comprehensive Cancer Center), Anette Sundstedt, Remi Adelaiye‐Ogala(Roswell Park Comprehensive Cancer Center), Leigh Ellis(Roswell Park Comprehensive Cancer Center), Eric Ciamporcero(Roswell Park Comprehensive Cancer Center), Ashley Orillion(Roswell Park Comprehensive Cancer Center), Mona Celander(Active Biotech (Sweden))
Cited by 90
Related Papers
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2012|2k
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
|The Lancet|2014|750
External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing
|Cancer Research|2004|439
Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock
|Nature Immunology|2003|363